

90TH ADVISORY FORUM  
MADRID, 30NOV-01DEC 2023



# **VACCINATION OF POULTRY AGAINST HPAI – PART 1**

## **AVAILABLE VACCINES AND VACCINATION STRATEGIES**

Francesca Baldinelli  
Animal Health Team (AH)  
Biological Hazard & Animal Health and  
Welfare Unit (BIOHAW)

## TERM OF REFERENCES

1. Update on the available vaccines against HPAI for poultry
2. Vaccination strategies

➡ **available at:**

<https://www.efsa.europa.eu/en/efsajournal/pub/8271>

3. Surveillance in the vaccinated zone and/or vaccinated establishments
4. Restrictions and risk mitigation measures to be applied in a vaccinated establishment or a vaccination zone

➡ **by March 2024**





# TOR 1 – AVAILABLE VACCINES



# TOR 1 – VACCINE CHARACTERISTICS

Technology	Poultry species (experimental data)	Administration route	Vaccine name	Estimated antigenic distance	Lineage, clade	Predicted efficacy of a vaccine to stop sustained HPAIV transmission in a vaccinated population
Inactivated full virus	Chickens (Pekin ducks, turkeys)	Subcutaneous or intramuscular	Nobilis Influenza H5N2 <sup>(NL)</sup>	4.37	Eurasian H5	< 0.5 in chickens after 1 dose
Inactivated full virus	Poultry (Muscovy ducks)	Subcutaneous	Vaxigen Flu H5N8 <sup>(IT)</sup>	2.32	2.3.4.4b	in chickens >0.9 in Muscovy ducks <0.5 after 1 dose, >0.9 after 2 doses
Subunit	Chickens (Muscovy, Pekin, mule ducks, turkeys)	Subcutaneous	Volvac B.E.S.T. AI + ND <sup>(FR, IT)</sup>	4.18	2.3.2	in mule duck > 0.9 (after 2 doses) in Muscovy ducks 0.8-0.9 after 1 dose, >0.9 after 2 doses in Pekin ducks >0.9
Live vector	Chickens (ducks, turkeys)	In ovo or subcutaneous	Vectormune AI <sup>(IT, NL)</sup>	4.18	2.2	in chickens > 0.9 in turkeys 0.5-0.8
Replicon	(ducks, geese, chickens, zoo birds)	Intramuscular	Duck H5-SRV vaccine <sup>®(FR, HU)</sup>	2.32	2.3.4.4b	> 0.9 in mule ducks
Nucleic acids (DNA)	(chickens, turkeys)	Intramuscular	ExactVac – Vaxliant ENABLE adjuvant <sup>(IT, NL)</sup>	2.51	2.3.4.4a	<0.5 in chickens after 1 dose

# TOR 1 - RECOMMENDATIONS

- Generate **suitable and harmonised data on**:
  - the **onset and duration of immunity** particularly for long living poultry types
  - the **impact of maternal immunity**
  - the indications of vaccines for **poultry species other than chickens** and considering **different poultry production types**
  - **VE** to reduce  $R_0 < 1$  under **experimental** condition and to assess **effectiveness in field trials** taking into account regional differences
- The development of **mass applicable** AI vaccines
- The **rapidly update** if required based on the antigenic match; for this purpose, continuous surveillance efforts to **monitor virus evolution** are needed







# TOR 2 – VACCINATION STRATEGIES



## TOR 2 – VACCINATION SCENARIOS

Scenario 0 (S0)

**No vaccination**

Culling in all infected poultry farms

Scenario 1 (S1)


**No vaccination**

Culling in all infected poultry farms


Preventive ring **culling** in all poultry farms within **1-km** radius of infected poultry farms

## TOR 2 – TRANSMISSION MAPS


Rh are the between-farm reproduction numbers quantified using the kernel. Areas where  $R_h > 0.8$  are considered high-risk areas for transmission



(farm density > 0.54 farm/km<sup>2</sup>)



(farm density > 0.52 farm/km<sup>2</sup>)




(farm density > 0.84 farm/km<sup>2</sup>)




# TOR 2 – VACCINATION SCENARIOS

Results from the model simulation for each scenario in **France**




# TOR 2 – VACCINATION SCENARIOS

Results from the model simulation for each scenario in **France**



# TOR 2 – VACCINATION SCENARIOS

Results from the model simulation for each scenario in **France**



## TOR 2 – RECOMMENDATIONS

- To minimise the number of infected and culled farms and epidemic duration, **preventive vaccination of the most susceptible and/or infectious poultry species is recommended** in high-risk transmission areas. Depending on the region, these species are ducks, geese, turkeys and layers chickens
- In case of an outbreak in a high-risk transmission area, **emergency protective vaccination in a 3-km radius is recommended**, as it showed to be the most effective strategy among the three emergency vaccination scenarios tested
- **Monitoring of vaccine efficacy over time** should be planned under the implementation of every vaccination strategy, due to possible changes in the antigenicity of circulating HPAI viruses, changes that can also be accelerated by the selection pressure exerted by vaccine-induced immunity <sup>12</sup>





# THANKS TO ALL THE EXPERTS INVOLVED

## Working group experts

- BASTINO Eleonora (EMA)
- BORTOLAMI Alessio (EURL)
- FEDIAEVSKY Alexandre (WOAH)
- GONZALES Josè (WUR)
- GRASLAND Beatrice (ANSES)
- GUINAT Claire (ENVT)
- HARDER Timm (FLI)
- MIRAS Christine (CVMP, EMA)
- SCOLAMACCHIA Francesca (EURL)
- STEGEMAN Arjan (WUR)
- TERREGINO Calogero (EURL)
- VILTROP Arvo (EMU)


## Member State

- Hungary
- Italy
- France
- The Netherlands

## EFSA

- AZNAR Inmaculada
- BALDINELLI Francesca
- BROGLIA Alessandro
- LINDGREN KERO Linnea
- LANFRANCHI Barbara
- MUR Lina





**Thank you for your  
attention!**

**#OpenEFSA**



# STAY CONNECTED

## SUBSCRIBE TO

[efsa.europa.eu/en/news/newsletters](https://efsa.europa.eu/en/news/newsletters)

[efsa.europa.eu/en/rss](https://efsa.europa.eu/en/rss)

[Careers.efsa.europa.eu](https://careers.efsa.europa.eu) – job alerts



## FOLLOW US ON TWITTER

[@efsa\\_eu](https://twitter.com/efsa_eu)

[@methods\\_efsa](https://twitter.com/methods_efsa)

[@plants\\_efsa](https://twitter.com/plants_efsa)

[@animals\\_efsa](https://twitter.com/animals_efsa)



## FOLLOW US ON INSTAGRAM

[@one\\_healthenv\\_eu](https://www.instagram.com/one_healthenv_eu)



## LISTEN TO OUR PODCAST

Science on the Menu – Spotify, Apple Podcast and YouTube



## FOLLOW US ON LINKEDIN

[Linkedin.com/company/efsa](https://www.linkedin.com/company/efsa)



## CONTACT US

[efsa.europe.eu/en/contact/askefsa](https://efsa.europe.eu/en/contact/askefsa)

